This work builds on ongoing engagement from Shionogi, the originator of flomoxef, and includes:
🔹 Supporting evidence generation
🔹 Exploring access to lifesaving antibiotics for newborns with sepsis
🔹 Contributing to global efforts against antimicrobial resistance